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SHORT SUMMARY:  
Extended hepatic resections for intrahepatic cholangiocarcinoma is an independent 
risk factor for major complication but do not affect negatively oncologic outcomes. 
The importance of oncologic results of extended hepatic resections is that such 
resections could be performed for large tumors and may be in second line of 
treatment for patients with initially unresectable tumors.  
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ABSTRACT 
BACKGROUND: In patients with intrahepatic cholangiocarcinoma (ICC), extended 
liver resections (ELRs) increase the rate of resectability. The aims of the present 
study were to evaluate the morbidity and oncologic outcomes of ELR compared with 
other liver resections (LR) for ICC.  
METHODS: All LR for ICC that were performed in our center between January 1997 
and September 2013 and conducted with curative intent were included in this 
retrospective analysis. ELRs were defined by resections of ≥ 5 liver segments. The 
factors that influenced the occurrence of major complications (Clavien ≥ 3) and 
overall survival were tested with uni- and multivariate analyses.  
RESULTS: One hundred and seven patients (82 men and 25 women) were resected, 
and 27 (25.3%) underwent ELRs. Compared with the LRs, the ELRs were performed 
in larger tumors (p=0.003) and were significantly associated with more complex 
surgeries such as vascular (p<0.001) or biliary reconstructions (p<0.001). Multivariate 
analysis revealed that ELR was an independent risk factor for major complications 
(OR 6.2, [2.11 to 19.62], p<0.001). Compared with the other LRs, ELRs had no 
effects on overall survival (OS) or disease-free survival (p=0.881 and p=0.228, 
respectively). Perioperative blood transfusion (OR 2.51, [1.49 to 4.23], p<0.001), the 
presence of more than one nodule (OR 3.17, [1.67 to 5.97], p<0.001) and an age ≥ 
65 years (OR 1.72, [1.03 to 2.86)], p=0.036) were independent prognostic factors for 
overall survival.  
CONCLUSIONS: This study suggests that ELRs performed for large ICCs do not 
negatively affect oncological outcomes despite the increased risk of major 
complications.  
 
 
 
 
Word count abstract : 249 
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INTRODUCTION 
Liver resection (LR) is the most suitable curative treatment for intrahepatic 
cholangiocarcinoma (ICC). ICC has become a public health issue with an incidence 
that has increased in all Western countries in the last two decades1-4. Moreover, the 
prognosis for ICC has not or only slightly improved. Indeed, the median survival 
ranges between 18 and 39 months 5,6.  
This poor prognosis is first related to the high rate of recurrence, particularly during 
the first year following liver resection7, and to the low rate of resectability. Indeed, in 
the majority of cases, ICC arises in patients without identifiable underlying liver 
disease and is thus frequently diagnosed at a late stage with large tumors8-10. In 
these conditions, the only available curative resection options are extended liver 
resections (ELR) or orthotopic liver transplantation (OLT). Unfortunately, the first 
studies that reported on the primary results of OLT in ICC revealed five-year overall 
survival (OS) rate of only 25%11. These poor results are inconceivable in periods of 
liver graft scarcity. In contrast, with the recent progress in surgical techniques, 
perioperative management and postoperative care, ELR has become increasingly 
common, and the risks associated with these major procedures have decreased. For 
example, portal vein occlusion via ligation or embolization allows for the possibility of 
increasing the remaining liver and thus reducing the risk of liver failure following ELR. 
In recent years, our experiences have revealed an increase in the indications for ELR 
in ICC from 17% to one-third of cases (Figure 1.). However, this surgical 
aggressiveness has not yet been evaluated. Although some reports have analyzed 
the effects of vascular reconstruction on survival and outcome12, none have 
specifically compared ELR and LR in terms of outcomes and survival. 
The aim of the present study was to analyze the outcomes and survival following LR 
with curative intent for ICC with a special focus on ELR. 
Clean version 26/10/14 
METHODS 
Patients 
The study population included all with curative-intent LRs performed for mass forming 
type ICCs as defined by the liver Cancer Study Group of Japan at a single tertiary 
referral center between the 1st of January 1997 and the 1st of September 2013. 
Hepatocellular cholangiocarcinoma, gallbladder carcinoma, hilar cholangiocarcinoma 
and periductal infiltrating types were excluded from the analyses. The clinical data 
were retrospectively collected from an LR database and analyzed after institutional 
review board approval was obtained.  
Data were collected regarding demographics (i.e., age, sex and body mass index 
(BMI)), surgical variables, length of hospital stay, morbidity, postoperative 
chemotherapy and follow-up including disease recurrence and death.  
Pathological data, such as the tumor size, satellite nodes, lymph node involvement, 
UICC 7th edition TNM staging, perineural invasion and microvascular involvement, 
were collected. 
Surgery 
Prior to surgery, each patient was evaluated by thoracoabdominal computed 
tomography scans with intravenous contrast. Portal vein embolization was indicated 
when the Liver Resection Volume/total liver volume ratio was < 35%. Extended liver 
resection (ELR) was defined by the resection of five or more Couinaud liver 
segments. Right or left hepatectomy extended to segment 1 and right or left 
trisectionectomy were considered to be ELRs. All LRs were performed with curative 
intent by senior surgeons. Intraoperative ultrasounds of the liver were performed to 
ensure the extension and the resectability of the tumor. Vascular or biliary 
reconstructions (partial or complete) were performed when necessary. Vascular 
reconstructions were classified into the following three categories: portal vein 
reconstruction, inferior vena cava reconstruction, and hepatic artery reconstruction. In 
one case, LR was performed ex situ. The absence of bulky lymph nodes in the celiac 
or paraaortic area, the absence of tumor residue in the remnant liver and the 
absence of peritoneal extension defined curative hepatectomies. The resection 
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margin was classified as microscopically negative (R0) or positive (R1). When 
macroscopic tumoral tissue was left in situ, the resection was R2. 
Postoperative morbidity  
Postoperative morbidity was defined by any complication that occurred within 90 
days after the LR and was categorized according to the Dindo and Clavien 
classification13. Major complications (MC) were categorized as grades III to V in the 
Dindo and Clavien classification. Postoperative liver failure was defined by the “50-
50” criteria on postoperative day 5 as described by Balzan et al.14. Postoperative 
mortality was defined by the occurrence of death within 90 postoperative days.     
Survival Analyses  
The end of the follow-up was set to be between the 1st of December 2013 and the 1st 
of January 2014 or the time of death. Overall survival was calculated from the date of 
the intervention to the time of death (regardless of cause) or to the end of follow-up. 
Disease-free survival (DFS) was calculated from the date of the intervention to the 
time of recurrence or the time of death. To identify the prognostic factors for overall 
survival, the following data were analyzed: age, gender, ASA score ≥ 2, BMI ranking 
in categories (<25, 25-30 and >30), known cirrhosis, neoadjuvant chemotherapy, 
portal embolization, ELR, vascular resection, bile duct resection, lymph node 
dissection, resectability, perioperative blood transfusion, major complications, tumor 
size (≥ 5 cm), ≥ 1 node, macrovascular invasion, perineural invasion, positive lymph 
nodes, and adjuvant chemotherapy.  
Statistical Analyses  
Comparisons were made between the patients who underwent ELR and those who 
underwent other LRs. Qualitative variables are expressed as numbers with 
percentages and were compared with chi square tests or Fisher’s tests when 
necessary. Quantitative variables are expressed as the mean ± the standard 
deviation (SD) or the median and were compared using Student’s t tests or Mann–
Whitney U tests as appropriate. Univariate analyses were conducted on the variables 
that are known to have roles in postoperative major complications. All variables with 
p values <0.1 in the univariate analyses were entered into the multivariate analysis 
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that utilized a multiple logistic regression model. The most suited model was then 
selected using a stepwise method based on the Akaike criteron. 
The cumulative survival rate was estimated by the Kaplan-Meier method, and the 
survival curves were compared with the log rank test. The univariate analyses were 
conducted between the relevant clinicopathologic variables and the cumulative 
survival rates using the log rank test. The Cox proportional hazard model was utilized 
with all variables with p values < 0.1 in the univariate analyses and the variables that 
are known to influence survival. Stepwise method was also used to select the most 
suited model. P<0.05 was considered statistically significant in all comparisons. The 
analyses were performed with R statistical software (http://www.r-project.org/). 
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RESULTS 
Demographic and operative data  
During the study period, 107 patients underwent LR with curative intent for ICC (82 
men and 25 women). ELR was performed in 27 cases (25%). The preoperative data 
were compared and are shown in the Table 1. The mean ages were 61.4 ± 10.2 
years and 65.6 ± 8.9 years in the ELR and other LR groups, respectively (p=0.07). 
The patients’ BMIs were greater than 30 in three cases (11.11%) in the ELR group 
and in 21 cases in the other group (26.25%; p=0.2). No differences were found in 
either portal vein embolization or neoadjuvant chemotherapy rates between the two 
groups. The tumor size was significantly larger in the ELR than in the other LR group 
(7.8 ± 2.46 cm vs. 6.14 ± 3.14, respectively, p=0.003). ELRs were associated with 
more complex reconstructions. Indeed, vascular reconstructions were required in 
eight cases (29.63%) in the ELR group vs. three (3%) in the other LR group 
(p<0.001), and included portal vein reconstructions in six vs. one (p<0.001), inferior 
vena cava reconstructions in four vs. two (p=0.03) and hepatic artery reconstructions 
and in three vs. zero (p=0.01) of the cases in each respective group. Bile duct 
resections were required for eight patients (29.63%) in the ELR and two (2.5%) 
patients in the other LR group (p<0.001).  
R0 resection rate was similar in both group (74% vs 79% in ELR and other LR group 
respectively, p=0.81). 
The major complication and surgical revision rates were significantly higher in the 
ELR group than in the other LR group (59.26 vs. 15% (p=0.01) and 29.63 vs. 7.5% 
(p=0.06), respectively). The liver dysfunction rates were not statistically different 
(7.41 and 10% in the ELR and other LR group, respectively).  
Hospital stay was significantly longer in ELR group than in other LR group ( 13 ± 16.7 
days [4-70] and 10 ± 13.3 days [4-91], respectively (p=0.02). 
The 90-day mortality rate was 9.2% (10 patients) across the entire population, and 
there was no difference between the two groups (p=1). We have summarized all 
causes of death in the Supplementary Table 1. Two patients (7.4%) in the ELR group 
died; the first death was linked to portal vein and arterial thromboses following an 
extended right hepatectomy, and the second was linked to major sepsis.  
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Risk Factors for Major Complications 
Twenty-eight patients developed major complications (26%). Among the 14 factors 
assessed by univariate analyses (Table 2.), ELR (p<0.001), vascular reconstruction 
(p<0.001), bile duct resection (p=0.02) and extended lymphadenectomy (p=0.01) 
were significantly associated with increased risks of major complication. In the 
multivariate analysis, ELR (OR=6.2, (2.11-19.62), p<0.001) was the only remaining 
independent risk factor for major complications.  
 
Survival and recurrence analyses  
All patients were included in the overall and disease-free survival analyses. The 
median overall survival of the entire cohort was 32.8 months, and the one-, three- 
and five-year actuarial survival rates were 79.8, 49.4 and 34.6%, respectively.  
Recurrence was observed in 16 ELR patients (59.26%) and 44 other LR patients 
(55%; p=0.81). Fifty-five percent of the recurrences were at least intrahepatic. The 
median disease-free survival of the entire cohort was 10.73 months, and the one-, 
three- and five-year actuarial survival rates were 49.68, 25.7 and 17.4%, respectively. 
The overall survival rates and disease-free survival rates were not significantly 
different between the ELR and the other LR groups, p=0.881 and p=0.228, 
respectively; Figure 2. 
Univariate and Multivariate Analysis of Variables Affecting Overall Survival  
The variables that were thought to have effects on overall survival are reported in 
Table 3. Extended lymphadenectomy (p=0.05), perioperative allogenic blood 
transfusion (p<0.001), tumor size ≥ 5 cm (p=0.005), multinodular tumor (p<0.001) 
and positive lymph node involvement (p=0.02) were associated with poor overall 
survival. Neither vascular reconstruction nor extended resection significantly affected 
overall survival. The multivariate analysis revealed that an age ≥ 65 years (OR 1.72, 
(1.03-2.86), p=0.036), a perioperative blood transfusion (OR 2.51, (1.49 to 4.23), 
p<0.001) and the presence of more than one nodule (OR 3.17, (1.67 to 5.97), 
p<0.001) were independent risk factors for overall survival (Figure 3).   
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DISCUSSION 
Liver resection with curative intent remains the best therapeutic option for ICC 
patients15. Advances in anesthesiology, liver surgery and postoperative care have 
enabled more extensive liver resections. The present study analyzed the outcomes of 
27 ELRs that were performed with the intent to cure ICC patients. Our results are the 
first to shed light on the surgical aggressiveness of the use of ELR for ICC compared 
with the use of less aggressive LRs. Indeed, we demonstrated that, despite an 
increase in the 90-day postoperative major morbidity, ELR resulted OSs and DFSs 
that were similar to those of non-extended LRs that were performed for smaller 
tumors. These results are strengthened by the absence of patients lost to follow up in 
our cohort.  
The multivariate analysis of the factors associated with major complications revealed 
that ELR was the only independent risk factor. In this series, the higher rate of MC in 
the ELR group was probably linked to the complexity of surgeries, which included 
more vascular or biliary resections and reconstructions. The most frequent 
complication was biliary leakage, and this finding accords with a finding of our 
previous report that showed that major LR was an independent risk factor for the 
occurrence of biliary leakage16. These results have recently been confirmed by 
Zimmity et al. in a large retrospective study of approximately 2628 LRs that showed 
that increased LR complexity is correlated with the rate of biliary leakage but not with 
the rates of hemorrhage or perihepatic abscesses17. In the present series, the overall 
90-day mortality was higher than the recent report of Ali et al.12. This difference could 
be partially explained by the lack of selection criterion such as the age or underlying 
liver disease.  
 
Although portal vein embolization (PVE) was considered preoperatively in all cases, 
two patients (7.4%) in the ELR group who did not have PVEs developed 
postoperative liver dysfunction. These results are in line with those of a previously 
published study18,19. However, these findings might indicate that the operative risk 
was underestimated in the ICC patients, and therefore inadequate preoperative and 
operative management was applied. This underestimation is likely based on the false 
belief that ICCs arise in normal underlying liver parenchyma. Indeed, one might 
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consider that the increased incidence of ICC in Western countries might be related to 
the rise of metabolic syndromes and insulin resistance3,20, which would lead us to 
believe that ICCs often occur in liver parenchyma with steatosis or steatohepatitis 
and might partially explain the rate of postoperative liver failure21. 
Similarly, Cauchy et al. recently demonstrated that LR for HCC associated with 
metabolic syndrome is significantly associated with an elevated risk of postoperative 
morbidity22. Based on these results, it is reasonable to suggest that improvements in 
pre- and perioperative management should be implement especially when ELR is 
considered for ICC. 
The main result of the present study is that ELR performed for the largest ICC neither 
negatively influenced OS nor DFS compared with non-ELR performed for the 
smallest tumors. Indeed, the actuarial five-year OS of the patients who underwent 
ELR was 32.3%, and this result is largely similar to those reported by Cho et al. in 
their series of 63 LRs for which the five-year cumulative survival rate was 31.8%23. 
Beyond the fact that these results validate our aggressive policy, they allow us to 
further broaden the criteria for the patients who are eligible for curative treatments; 
specifically some patients with conditions currently considered unresectable could be 
included. Indeed, the challenge henceforth is to identify and validate therapeutic 
strategies that can reduce tumor size and enable curative resection through ELR. 
Among the different possibilities, transcatheter arterial chemoembolization (TACE) 
using cisplatin might represent a promising approach24. TACE allows for the delivery 
of increasing local concentrations of chemotherapy without damaging the healthy 
liver tissue and reduces systemic side effects24. Accordingly, Kim et al. reported 
interesting results about down-staging ICC following TACE25. Similarly, the intra-
arterial injection of yttrium-90-labeled (yttrium-90) is a persuasive therapeutic option 
that can decrease tumor and increase the remnant liver volume as has recently been 
shown in HCC26. We previously demonstrated the potential of yttrium-90 in ICC 
recurrence following primary curative resection to ensure prolonged survival7. Among 
46 patients with ICCs that were initially considered unresectable, Mouli et al. reported 
that that 10.8% (n=5) were converted to resectable statuses and were successfully 
treated with curative resection after yttrium-90 27. These results are reinforced by a 
recently published clinical case28. Altogether, expert centers play a crucial role in the 
management of ICC and contribute to the optimization of the management of these 
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cancers especially when large cancers that are potentially unresectable and require 
collaboration between surgeons, oncologists and radiologists are being considered.  
Finally, our multivariate analysis of the factors that affected the OS demonstrated that 
only an age over 65 years, the presence of satellite nodules and the requirement for 
a perioperative blood transfusion were closely correlated with the poorest prognoses. 
In this series, blood transfusions were required in 29.63% of the ELR group, which is 
not different from previously reported results19. Perioperative blood transfusion has 
been highlighted frequently as an important predictive factor for perioperative 
mortality and survival in liver cancer surgery for the last 20 years. A recent meta-
analysis of the effects of perioperative blood transfusions in patients with 
hepatocellular carcinomas confirmed that perioperative blood transfusions are 
associated with an elevated risk of death at three and five years and an increased 
risk of tumor recurrence 29. Several authors have argued that these effects are due to 
the immunosuppressive effects of blood transfusion and support the role of the 
immune system in the control of tumor proliferation and progression. Accordingly, it is 
important to reassert that perioperative allogenic blood transfusion should not be 
avoided when possible and to emphasize surgical techniques that minimize blood 
loss. These data further strengthen the need to manage these patients in expert 
centers to improve the overall prognoses of these tumors. 
Obviously, the current study has some limitations. Even if there was no significant 
difference between the ELR group and the other LR group on confounding variables, 
there was potentials selection bias. The sample size of the ELR group was quite 
small even it represented a quarter of our entire population and further studies are 
needed to confirm the results.  
In conclusion, for the first time, this study supports the notion that ELRs for large 
ICCs do not negatively affect oncological outcomes. These findings argue in favor of 
aggressive therapeutic strategies for ICC to increase the rate of resectability. In view 
of ELR results on survival, we can assume that the combination of a neoadjuvant 
therapy, such as yttrium-90, to decrease the tumor size and increase the remnant 
liver with ELR is an appealing strategy that should be explored in the near future. 
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Figure 1. Evolution of the frequency with which ELR were performed before and after 
2008. 
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Figure 2. Overall and disease-free survival after liver resection according to 
extended liver resection status (ELR) (continuous line: non-ELR, dotted line: ELR). 
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Figure 3. Overall survival after liver resection according to transfusion status 
(continuous line: no transfusion, dotted line: transfusion) and the presence of more 
than one nodule (continuous line: nodule = 1, dotted line: > 1 nodule). 
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Table 1.  
Patient characteristics, Perioperative and outcome data according to extended 
resection status 
 Extended liver resection  
 
Yes No p value 
  
(n=27) (n=80) 
  
Age (mean±sd) 61.4±10.2  65.6±8.9  0.07 
Range 40-79  39-83   
Gender F:M 9:18  16:64  0.25 
BMI* 
    0.2 
≤ 25 12 (44.44) 34 (42.50)  
25-30 11 (40.74) 23 (28.75)  
≥ 30 3 (11.11) 21 (26.25)  
ASA score** 
    1 
<2 21 (77.78) 62 (77.50)  
≥2 6 (22.22) 16 (20.00)  
Known cirrhosis 4 (14.81) 25 (31.25) 0.14 
Portal embolization 6 (22.22) 8 (10.00) 0.18 
Neoadjuvant chemotherapy  6 (22.22) 9 (11.25) 0.19 
Blood transfusion  8 (29.63) 21 (26.25) 0.9 
Vascular resection  
     
Portal vein resection 6 (22.22) 1 (1.25) <0.001 
Inferior vena cava resection 4 (14.81) 2 (2.50) 0.03 
Hepatic artery resection 3 (11.11) 0 (0.00) 0.01 
Bile duct resection 8 (29.63) 2 (2.50) <0.001 
Resectability 
    0.81 
R0 20 (74.07) 63 (78.75)  
R1 7 (25.93) 17 (21.25)  
Tumor  size (cm,mean ± sd) 7.8 ± 2.46  
6.14 ± 
3.14 
 0.003 
Major complication*** 16 (59.26) 12 (15.00) <0.001 
Biliary fistulas 10 (37.04) 11 (13.75) 0.01 
Surgical revision 8 (29.63) 6 (7.50) 0.006 
Hospital stay (days, median ± sd) 13 ± 16.7  10 ± 13.3  0.02 
Range 4-70  4-91   
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90d mortality  2 (7.41) 8 (10.00) 1 
Recurrence 
    0.81 
Yes 16 (59.26) 44 (55.00)  
No 10 (37.04) 34 (42.50)   
* 3 NA, **2 NA,  *** Clavien ≥ 3      
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Table 2. 
  Univariate and Multivariate analyses  of major complications factors 
  Univariate analysis 
 
Multivariate Analysis 
Factors  Major Complications 
  
YES NO 
 
    
(n=28) (n=79) 
p value 
  
Odds ratio (95% confidence Interval) p 
value 
Age      0.39  - - 
< 65  15 (53.57) 33 (41.77)     
≥ 65  13 (46.43) 46 (58.23)     
Gender      0.12  - - 
Male  18 (64.29) 64 (81.01)     
Female   10 (35.71) 15 (18.99)     
BMI*      0.52  - - 
≤ 25  14 (50.00) 32 (40.51)     
25-30  7 (25.00) 27 (34.18)     
≥ 30  5 (17.86) 19 (24.05)     
ASA score**      0.52  - - 
<2  4 (14.29) 18 (22.78)     
≥2  23 (82.14) 60 (75.95)     
Known cirrhosis      0.14  - - 
Yes  4 (14.29) 25 (31.65)     
No  24 (85.71) 54 (68.35)     
Neo adjuvant 
chemotherapy      0.53  -  
Yes  5 (17.86) 10 (12.66)     
No  23 (82.14) 69 (87.34)     
Portal embolization      1  -  
Yes  3 (10.71) 11 (13.92)     
No  25 (89.29) 68 (86.08)     
Operative time      0.71  -  
≥ 180 min   13 (46.43) 32 (40.51)     
< 180 min  15 (53.57) 66 (83.54)     
Tumor size       0.037  - - 
< 5cm  4 (14.29) 30 (37.97)     
≥ 5 cm  24 (85.71) 49 (62.03)     
Blood transfusion      0.052  2.91(0.96-8.97) 0.056 
Yes  12 (42.86) 17 (21.52)     
No  16 (57.14) 62 (78.48)     
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Extended liver resection      <0.001  6.2(2.11-19.62) <0.001 
Yes  16 (57.14) 11 (13.92)     
No  12 (42.86) 68 (86.08)     
Vascular resection      <0.001  3.91(0.74-24.1) 0.11 
Yes  8 (28.57) 3 (3.80)     
No  20 (71.43) 76 (96.20)     
Bile duct resection      0.02  - - 
Yes  6 (21.43) 4 (5.06)     
No  25 (89.29) 75 (94.94)     
Extended 
lymphadenectomy      0.01  2.51(0.89-7.01) 0.08 
Yes  16 (57.14) 22 (27.85)     
No  12 (42.86) 57 (72.15)     
Resectability      0.24  - - 
R0  19 (67.86) 64 (81.01)     
R1   9 (32.14) 15 (18.99)         
* 3 NA, **2 NA          
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Table 3. 
    Risk factors for overall survival 
Factors    Univariate Analysis  Multivariate Analysis 
  
1 y 3 y 5 y n(%) p value   Hazard ratio (95% confidence Interval) p value 
Age      0.09  1.72(1.03-2.86) 0.036 
<65 86.8 60.5 39.6 48 (44.86)     
≥ 65 70.6 41 30.9 59 (55.14)     
Gender      0.86  - - 
F 71.1 44 36.7 25 (23.36)     
M 79.6 50.6 34.2 82 (76.64)     
BMI *      0.59  - - 
≤ 25 73.4 59.7 43.1 46 (42.99)     
25-30 93.7 39.4 22.5 34 (31.78)     
≥ 30 78.9 47.8 38.3 24 (22.43)     
Known cirrhosis      0.55  - - 
Yes 79.3 40.9 31.8 29 (27.10)     
No 81 53.6 36.4 78 (72.90)     
Neo adjuvant 
chemotherapy 
     0.7  - - 
Yes 71.8 53.8 21.5 15 (14.02)     
No 81.1 48.6 36.3 92 (85.98)     
Portal embolization      0.097  - - 
Yes 77.9 33.4 11 14 (13.08)     
No 80 51.1 37.4 93 (86.92)     
Extended liver resection      0.881  - - 
Yes 84.3 47 32.3 27 (25.23)     
No 78.5 50 35.3 80 (74.77)     
Vascular resection      0.78  - - 
Yes 64.9 64.9 43.3 11 (10.28)     
No 78.8 48.4 34.2 96 (89.72)     
Bile duct resection      0.68  - - 
Yes 77.1 61.7 41.1 10 (9.35)     
No 79.9 48.3 34.1 97 (90.65)     
Extended 
lymphadenectomy      0.05  - - 
Yes 74.6 37.3 17.5 38 (35.51)     
No 82.5 55 41.9 69 (64.49)     
Resectability      0.23  - - 
R0 81.4 52.5 37.1 83 (77.57)     
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R1 75 40.6 27.1 24 (22.43)     
Blood transfusion       <0.001  2.51(1.49-4.23) < 0.001 
Yes 65.5 40 6.8 29 (27.10)     
No 85.4 53.2 45.5 78 (72.90)     
Major complications       0.057  - - 
Yes 59.6 50 19 28 (26.17)     
No 86.9 49.9 39.5 79 (73.83)     
Tumor size       0.0056  - - 
< 5cm 91 76.7 51.6 34 (31.78)     
≥ 5 cm 71.4 36.7 26.7 73 (68.22)     
Nodule       <0.001  3.17(1.67-5.97) <0.001 
1 80 57.6 39.9 85 (79.44)     
> 1 75.9 7.6 0 22 (20.56)     
Macrovascular invasion      0.2  - - 
Yes 75.5 36.7 0 14 (13.08)     
No 80.3 51 37.8 93 (86.92)     
Microvascular invasion       0.059  - - 
Yes 69.4 34.1 26.3 42 (39.25)     
No 86.1 58.6 39.3 65 (60.75)     
Perineural invasion       0.93  - - 
Yes 77.9 48.2 32.2 25 (23.36)     
No 79.9 50 35.3 80 (74.77)     
Positiv lymph nodes       0.02  1.71(0.95-3.07) 0.07 
Yes 84.1 22.5 7.5 20 (18.69)     
No 78.9 55.5 40.6 87 (81.31)     
Adjuvant chemotherapy      0.248  - - 
Yes 87.1 31.3 15.7 17 (15.89)     
No 78.4 51.7 36.8 90 (84.11)         
* 3 NA 
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Supplementary Table 1. Summarized of 90-day mortality causes.  
 
Groupe  Age/Gender Underlying liver disease  Cause(s) of death  
Time of Death  
(days after 
surgery) 
Other LR 67/M Cirrhosis  Pulmonary infection              42 
Other LR 64/F - Biliary leakage and sepsis             20 
Other LR 77/M - Biliary leakage and sepsis             86 
Other LR 72/M - Liver failure               7 
Other LR 72/M - NA             70 
Other LR 83/M Cirrhosis Liver failure and pulmonary infection               5 
Other LR 75/F - Massive hemorrhage             13 
Other LR 81/M - Cardiac failure               4 
          
ELR 64/F - Portal vein and hepatic arterial thrombosis               4 
ELR 72/M Cirrhosis  Wound infection with major sepsis             10 
ELR = Extended Liver Resection ; LR = Liver resection ; M=Male ; F=Female  
 
 
 
